Targeting a unique EGFR epitope with monoclonal antibody 806 activates NF-κB and initiates tumour vascular normalization

Monoclonal antibodies (mAbs) and tyrosine kinase inhibitors targeting the epidermal growth factor receptor (EGFR), which is often pathogenetically overexpressed or mutated in epithelial malignancies and glioma, have been modestly successful, with some approved for human use. MAb 806 was raised again...

Descripción completa

Detalles Bibliográficos
Autores principales: Gan, Hui K, Lappas, Martha, Cao, Diana X, Cvrljevdic, Anna, Scott, Andrew M, Johns, Terrance G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2009
Materias:
Molecular Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4516546/
https://www.ncbi.nlm.nih.gov/pubmed/19432811
http://dx.doi.org/10.1111/j.1582-4934.2009.00783.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4516546/
https://www.ncbi.nlm.nih.gov/pubmed/19432811
http://dx.doi.org/10.1111/j.1582-4934.2009.00783.x

Ejemplares similares